Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Ascendis Pharma (Nasdaq: ASND) reported third-quarter 2026 product revenue of €366 million, up 89% from a year earlier. Total revenue reached €370 million versus €214 million. YORVIPATH contributed €291 million, SKYTROFA €59 million and YUVIWEL €16 million. Operating profit rose to €125 million from €11 million, with margin expanding to 34% from 5%. Net profit was €74 million, or €1.08 per diluted share, versus a €61 million loss.
Quarterly operating cash flow was €189 million; Ascendis expects at least €600 million for full-year 2026. Cash reached €964 million at September 30, versus €616 million at year-end 2025. Share repurchases totaled $459 million through November 11. TransCon CNP received positive EU committee opinions; Ascendis expects a final European Commission decision in Q4 2026 and plans a German launch in Q1 2027. Infant trial data showed growth benefits and stabilized or improved skull-base narrowing.
Ascendis Pharma (ASND) executives will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2026. The London event is scheduled for 11:30 a.m. GMT / 6:30 a.m. Eastern Time / 3:30 a.m. Pacific Time. A live webcast will be available through the Investors & News section at investors.ascendispharma.com, with a replay available shortly afterward for 30 days.
Ascendis Pharma (ASND) received a positive European regulatory opinion recommending continued orphan designation for once-weekly TransCon CNP for children with achondroplasia. Final European Commission adoption would provide 10 years of orphan market exclusivity.
The recommendation follows a positive opinion supporting EU marketing authorization for children aged two years and older whose growth plates remain open. Ascendis expects the Commission’s final marketing authorization decision in Q4 2026. If authorized, the company expects its first EU launch, under the name YUVIWEL, in Germany during Q1 2027. The FDA approved the treatment in February 2026 to increase linear growth in children aged two years and older with achondroplasia and open growth plates.
Ascendis Pharma (Nasdaq: ASND) plans to report third quarter 2026 financial results and provide a business update on November 12, 2026. Results are scheduled before U.S. financial markets open, followed by a conference call and live webcast at 8:00 a.m. Eastern Time. A webcast replay will be available on the company’s investor website for 30 days after the event.
Ascendis Pharma (ASND) reported sustained kidney-function improvements in adults with hypoparathyroidism treated with TransCon PTH for up to five years. The post-hoc pooled analysis included 139 treated patients from Phase 2 PaTH Forward and Phase 3 PaTHway. Mean estimated glomerular filtration rate (eGFR), a kidney-function measure, rose 7.2 mL/min/1.73 m2 at Week 26 and 9.6 at Week 52 from baseline. At Week 52, 68.9% achieved increases of at least 5 mL/min/1.73 m2; improvements persisted through trial completion.
Mean urine calcium fell from 396 mg/day at baseline to 170 mg/day at Week 52. At final visits, 98% were independent of active vitamin D and 95% of therapeutic calcium doses; 88% had normal albumin-adjusted serum calcium. No new safety signals emerged. Long-term follow-up was open-label, and 129 patients completed the final visit.
Ascendis Pharma (Nasdaq: ASND) received a positive CHMP opinion recommending EU marketing authorization for once-weekly TransCon CNP for children with achondroplasia. The recommendation covers children two years and older whose growth plates remain open. Ascendis expects a final European Commission decision in Q4 2026.
The application included three randomized, double-blind, placebo-controlled trials and up to three years of open-label extension data. If authorized, Ascendis expects its first EU launch under the YUVIWEL brand in Germany during Q1 2027. EMA will also review whether the medicine's orphan designation can be maintained.
Ascendis Pharma (ASND) will present hypoparathyroidism and achondroplasia program updates at ASBMR 2026 in Boston on October 9–12, 2026.
Combined data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials show normalization of bone mass and microarchitecture over five years in patients treated with palopegteriparatide. Achondroplasia presentations cover improved growth and physical functioning with navepegritide in the ApproaCH open-label extension, where participants know their treatment, and continued improvements in lower-limb alignment at Week 104. Another presentation will cover 78-week results from the Phase 2 COACH trial of navepegritide combined with lonapegsomatropin.
Ascendis Pharma (ASND) will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity, following the effectiveness of a previously announced termination of its collaboration with Novo Nordisk.
After termination, all licenses granted to Novo Nordisk in these areas, including for once-monthly TransCon Semaglutide, revert fully to Ascendis and neither party has ongoing financial obligations to the other. Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications, and to advance once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide, as a potential treatment for obesity and type 2 diabetes. The company intends to apply its TransCon platform and “algorithm for product innovation” to pursue therapies it believes may have best-in-class potential.
Ascendis Pharma (ASND) announced that its board has authorized a share repurchase program for up to $400 million of the company’s ordinary shares.
Repurchases may be executed from time to time, in amounts management deems appropriate, using methods such as open market purchases, privately negotiated transactions, block trades, accelerated share repurchases, and 10b5-1 trading plans, or a combination of these. The timing and size of buybacks will depend on factors including market conditions and share price. The authorization does not obligate Ascendis to repurchase any specific number of shares and may be modified, suspended, or terminated at any time without notice.
Ascendis Pharma (ASND) reported 52-week data from the open-label sentinel cohort of the pivotal Phase 2 reACHin trial of once-weekly TransCon CNP (navepegritide) in seven treatment-naïve infants aged 0 to <2 years with achondroplasia.
All children showed stable or improved Achondroplasia Foramen Magnum Score (AFMS), with a mean increase in sagittal foramen magnum diameter of +3.15 mm and no decompression surgeries over 52 weeks. Linear growth improved, with a mean change in ACH-specific supine length Z-score of +0.42 and mean annualized growth velocity of 9.9 cm/year. Pharmacokinetics were comparable to those observed in older children, supporting the 100 μg/kg/week dose.
TransCon CNP was generally well tolerated, with no injection site reactions, deaths, fractures, bone-related safety events, symptomatic hypotension, treatment-related adverse events, or treatment disruptions or discontinuations reported in this cohort.